Characterization and evaluation of a new oncolytic Vaccinia Virus strain LIVP6.1.1 for canine cancer therapy

Gentschev, Ivaylo; Patil, Sandeep; Adelfinger, Marion; Weibel, Stephanie; Geissinger, Ulrike; Frentzen, Alexa; Chen, Nanhai G.; Yu, Yong A.; Zhang, Qian; Szalay, Aladar A.

doi:10.4161/bioe.22462

Cited by 22 publications

(30 citation statements)

References 20 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…GLV‐1h109, a derivate of GLV‐1h68 armed with an anti‐vascular endothelial growth factor single chain antibody, had also shown oncolytic potency against canine soft tissue sarcoma and in a prostatic carcinoma in vivo model and induced intense intratumoural infiltration of host immune cells in tumour‐bearing mice . However, an unarmed, less virulent Lister strain virus, LIVP1.1.1, showed even better oncolytic efficacy against canine soft tissue sarcomas in preclinical studies than GVL‐1h68, thus resulting in isolation of LIV6.1.1 . LIV6.1.1 is a wild‐type Lister strain vaccinia virus and has no genetic manipulations but TK is naturally inactivated and the virus has different mutations compared with GLV‐1h68 .…”

Section: Discussionmentioning

confidence: 99%

“…However, an unarmed, less virulent Lister strain virus, LIVP1.1.1, showed even better oncolytic efficacy against canine soft tissue sarcomas in preclinical studies than GVL‐1h68, thus resulting in isolation of LIV6.1.1 . LIV6.1.1 is a wild‐type Lister strain vaccinia virus and has no genetic manipulations but TK is naturally inactivated and the virus has different mutations compared with GLV‐1h68 . LIV6.1.1 is able to kill canine soft tissue sarcoma, melanoma, osteosarcoma and prostatic sarcoma cell lines and efficacy was shown in soft tissue sarcoma and prostatic carcinoma xenografts as well .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Anti‐tumour activity of oncolytic Western Reserve vaccinia viruses in canine tumour cell lines, xenografts, and fresh tumour biopsies

Autio

Knuuttila

Kipar

et al. 2014

Vet Comparative Oncology

View full text Add to dashboard Cite

Cancer is one of the most common reasons for death in dogs. One promising approach is oncolytic virotherapy. We assessed the oncolytic effect of genetically modified vaccinia viruses in canine cancer cells, in freshly excised tumour biopsies, and in mice harbouring canine tumour xenografts. Tumour transduction efficacy was assessed using virus expressing luciferase or fluorescent marker genes and oncolysis was quantified by a colorimetric cell viability assay. Oncolytic efficacy in vivo was evaluated in a nude mouse xenograft model. Vaccinia virus was shown to infect most tested canine cancer cell lines and primary surgical tumour tissues. Virus infection significantly reduced tumour growth in the xenograft model. Oncolytic vaccinia virus has antitumour effects against canine cancer cells and experimental tumours and is able to replicate in freshly excised patient tumour tissue. Our results suggest that oncolytic vaccinia virus may offer an effective treatment option for otherwise incurable canine tumours.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Anti‐tumour activity of oncolytic Western Reserve vaccinia viruses in canine tumour cell lines, xenografts, and fresh tumour biopsies

Autio

Knuuttila

Kipar

et al. 2014

Vet Comparative Oncology

View full text Add to dashboard Cite

show abstract

“…13,18,19 GLV-1h68 was also developed from the Lister strain by inserting three expression cassettes encoding Renilla luciferase-Aequorea green fluorescent protein fusion (Ruc-GFP), LacZ, and β-glucuronidase into the F14.5L, J2R (thymidine kinase), and A56R (hemagglutinin) loci of the viral genome, respectively.…”

Section: Methodsmentioning

confidence: 99%

Antigen profiling analysis of vaccinia virus injected canine tumors

et al. 2014

Self Cite

View full text Add to dashboard Cite

“…An increased infiltration of neutrophils, macrophages and natural killer (NK) cells to the tumor site might be involved in the VACV-mediated immune response in different canine cancer xenograft models [37,38,40]. The presence of such activated inflammatory cells in the tumor tissue may enhance the antitumoral effect by increasing the phagocytic or cytotoxic activities of these cells [71,72].…”

Section: Oncolytic Virotherapy For Canine and Feline Cancersmentioning

confidence: 99%

Oncolytic Virotherapy of Canine and Feline Cancer

Gentschev

Patil

Petrov

et al. 2014

Viruses

Self Cite

View full text Add to dashboard Cite

Cancer is the leading cause of disease-related death in companion animals such as dogs and cats. Despite recent progress in the diagnosis and treatment of advanced canine and feline cancer, overall patient treatment outcome has not been substantially improved. Virotherapy using oncolytic viruses is one promising new strategy for cancer therapy. Oncolytic viruses (OVs) preferentially infect and lyse cancer cells, without causing excessive damage to surrounding healthy tissue, and initiate tumor-specific immunity. The current review describes the use of different oncolytic viruses for cancer therapy and their application to canine and feline cancer.

show abstract

Characterization and evaluation of a new oncolytic Vaccinia Virus strain LIVP6.1.1 for canine cancer therapy

Cited by 22 publications

References 20 publications

Anti‐tumour activity of oncolytic Western Reserve vaccinia viruses in canine tumour cell lines, xenografts, and fresh tumour biopsies

Anti‐tumour activity of oncolytic Western Reserve vaccinia viruses in canine tumour cell lines, xenografts, and fresh tumour biopsies

Antigen profiling analysis of vaccinia virus injected canine tumors

Oncolytic Virotherapy of Canine and Feline Cancer

Contact Info

Product

Resources

About